HCA Healthcare, Inc. (NYSE:HCA) Shares Sold by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. trimmed its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 0.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 37,496 shares of the company’s stock after selling 283 shares during the period. Daiwa Securities Group Inc.’s holdings in HCA Healthcare were worth $15,240,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Terra Nova Asset Management LLC raised its stake in shares of HCA Healthcare by 0.3% in the 3rd quarter. Terra Nova Asset Management LLC now owns 8,112 shares of the company’s stock valued at $3,297,000 after acquiring an additional 26 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its stake in shares of HCA Healthcare by 7.4% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 421 shares of the company’s stock valued at $171,000 after acquiring an additional 29 shares in the last quarter. Waldron Private Wealth LLC increased its position in HCA Healthcare by 1.8% in the 3rd quarter. Waldron Private Wealth LLC now owns 1,681 shares of the company’s stock worth $683,000 after buying an additional 29 shares during the period. Brookstone Capital Management increased its position in HCA Healthcare by 0.7% in the 3rd quarter. Brookstone Capital Management now owns 4,065 shares of the company’s stock worth $1,652,000 after buying an additional 30 shares during the period. Finally, UMB Bank n.a. increased its position in HCA Healthcare by 2.4% in the 3rd quarter. UMB Bank n.a. now owns 1,301 shares of the company’s stock worth $529,000 after buying an additional 30 shares during the period. 62.73% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at HCA Healthcare

In related news, EVP Michael S. Cuffe sold 8,358 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the completion of the sale, the executive vice president now owns 29,678 shares in the company, valued at approximately $11,438,494.76. This represents a 21.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the sale, the insider now owns 6,843 shares of the company’s stock, valued at $2,415,579. This represents a 29.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 15,155 shares of company stock worth $5,608,990 over the last 90 days. 1.70% of the stock is owned by insiders.

Analyst Ratings Changes

HCA has been the topic of several recent analyst reports. Oppenheimer lifted their price target on HCA Healthcare from $390.00 to $400.00 and gave the stock an “outperform” rating in a research report on Monday, October 28th. KeyCorp decreased their price objective on HCA Healthcare from $475.00 to $420.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Barclays decreased their price objective on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Wells Fargo & Company lifted their price objective on HCA Healthcare from $395.00 to $400.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 6th. Finally, Raymond James lowered HCA Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday. Six investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $385.00.

HCA Healthcare Price Performance

HCA Healthcare stock opened at $324.93 on Monday. The firm has a market cap of $82.30 billion, a P/E ratio of 14.59, a P/E/G ratio of 1.25 and a beta of 1.68. HCA Healthcare, Inc. has a 52 week low of $245.84 and a 52 week high of $417.14. The company has a debt-to-equity ratio of 48.71, a quick ratio of 1.00 and a current ratio of 1.12. The business’s fifty day moving average is $379.40 and its two-hundred day moving average is $358.70.

HCA Healthcare Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 27th. Stockholders of record on Friday, December 13th will be given a dividend of $0.66 per share. The ex-dividend date is Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.81%. HCA Healthcare’s payout ratio is currently 11.85%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.